Emergent Biosolutions Inc
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intrav… Read more
Market Cap & Net Worth: Emergent Biosolutions Inc (EBS)
Emergent Biosolutions Inc (NYSE:EBS) has a market capitalization of $414.17 Million ($414.17 Million) as of March 19, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #11727 globally and #5161 in its home market, demonstrating a -4.65% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Emergent Biosolutions Inc's stock price $8.00 by its total outstanding shares 51770857 (51.77 Million).
Emergent Biosolutions Inc Market Cap History: 2015 to 2026
Emergent Biosolutions Inc's market capitalization history from 2015 to 2026. Data shows change from $1.84 Billion to $414.17 Million (-11.35% CAGR).
Emergent Biosolutions Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Emergent Biosolutions Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.86x
Emergent Biosolutions Inc's market cap is 0.86 times its annual revenue
1.00x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
12.17x
Emergent Biosolutions Inc's market cap is 12.17 times its annual earnings
9.89x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.70 Billion | $488.80 Million | $51.80 Million | 3.48x | 32.82x |
| 2017 | $2.41 Billion | $560.90 Million | $82.60 Million | 4.29x | 29.13x |
| 2018 | $3.07 Billion | $782.40 Million | $62.70 Million | 3.92x | 48.95x |
| 2019 | $2.79 Billion | $1.11 Billion | $54.50 Million | 2.53x | 51.25x |
| 2020 | $4.64 Billion | $1.58 Billion | $305.80 Million | 2.94x | 15.17x |
| 2021 | $2.25 Billion | $1.77 Billion | $219.50 Million | 1.27x | 10.25x |
| 2022 | $611.41 Million | $1.12 Billion | -$223.80 Million | 0.55x | N/A |
| 2023 | $124.25 Million | $1.05 Billion | -$760.50 Million | 0.12x | N/A |
| 2024 | $494.93 Million | $1.04 Billion | -$190.60 Million | 0.47x | N/A |
| 2025 | $639.89 Million | $742.90 Million | $52.60 Million | 0.86x | 12.17x |
Competitor Companies of EBS by Market Capitalization
Companies near Emergent Biosolutions Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Emergent Biosolutions Inc by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #422 globally with a market cap of $51.61 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #432 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #452 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #422 | Zoetis Inc | NYSE:ZTS | $51.61 Billion | $117.35 |
| #432 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.31 |
| #452 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Emergent Biosolutions Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Emergent Biosolutions Inc's market cap moved from $1.84 Billion to $ 414.17 Million, with a yearly change of -11.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $414.17 Million | -35.28% |
| 2025 | $639.89 Million | +29.29% |
| 2024 | $494.93 Million | +298.33% |
| 2023 | $124.25 Million | -79.68% |
| 2022 | $611.41 Million | -72.83% |
| 2021 | $2.25 Billion | -51.48% |
| 2020 | $4.64 Billion | +66.08% |
| 2019 | $2.79 Billion | -8.99% |
| 2018 | $3.07 Billion | +27.57% |
| 2017 | $2.41 Billion | +41.50% |
| 2016 | $1.70 Billion | -7.66% |
| 2015 | $1.84 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Emergent Biosolutions Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $414.17 Million USD |
| MoneyControl | $414.17 Million USD |
| MarketWatch | $414.17 Million USD |
| marketcap.company | $414.17 Million USD |
| Reuters | $414.17 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.